within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB10_PeginterferonAlfa2b;

model PeginterferonAlfa2b
  extends Pharmacolibrary.Drugs.ATC.L.L03AB10;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L03AB10</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Peginterferon alfa-2b is a pegylated recombinant interferon used as an antiviral and antineoplastic agent, primarily in the treatment of chronic hepatitis C and B infections. It has also been explored in some malignancies. While widely used in the 2000s and 2010s, direct-acting antivirals have largely replaced it in hepatitis C therapy. It remains approved and is occasionally used today in specific settings.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with chronic hepatitis C receiving subcutaneous doses.</p><h4>References</h4><ol><li><p>Huang, YW, et al., &amp; Larouche, R (2022). Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial. <i>British journal of clinical pharmacology</i> 88(5) 2396–2407. DOI:<a href=&quot;https://doi.org/10.1111/bcp.15176&quot;>10.1111/bcp.15176</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34907578/&quot;>https://pubmed.ncbi.nlm.nih.gov/34907578</a></p></li><li><p>Miyachi, N, et al., &amp; Qin, A (2021). Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration. <i>Clinical drug investigation</i> 41(4) 391–404. DOI:<a href=&quot;https://doi.org/10.1007/s40261-021-01026-5&quot;>10.1007/s40261-021-01026-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33725322/&quot;>https://pubmed.ncbi.nlm.nih.gov/33725322</a></p></li><li><p>Xu, C, et al., &amp; Sniukiene, V (2013). Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C. <i>European journal of clinical pharmacology</i> 69(12) 2045–2054. DOI:<a href=&quot;https://doi.org/10.1007/s00228-013-1574-9&quot;>10.1007/s00228-013-1574-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23975236/&quot;>https://pubmed.ncbi.nlm.nih.gov/23975236</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end PeginterferonAlfa2b;
